UBS Group
IRON icon

UBS Group’s Disc Medicine IRON Stock Holding History

UBS Group’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.12M Buy
110,971
+12,350
+13% +$849K ﹤0.01% 3681
2026
Q1 		$6.31M Sell
98,621
-17,491
-15% -$1.21M ﹤0.01% 3820
2025
Q4 		$9.22M Sell
116,112
-55,511
-32% -$4.69M ﹤0.01% 3372
2025
Q3 		$11.3M Buy
171,623
+26,074
+18% +$1.55M ﹤0.01% 3157
2025
Q2 		$7.71M Buy
145,549
+72,921
+100% +$3.43M ﹤0.01% 3393
2025
Q1 		$3.61M Buy
72,628
+48,286
+198% +$2.68M ﹤0.01% 4125
2024
Q4 		$1.54M Sell
24,342
-8,750
-26% -$506K ﹤0.01% 4963
2024
Q3 		$1.63M Sell
33,092
-44,586
-57% -$2.09M ﹤0.01% 4204
2024
Q2 		$3.5M Buy
77,678
+14,676
+23% +$499K ﹤0.01% 3197
2024
Q1 		$3.92M Buy
63,002
+49,380
+363% +$3.2M ﹤0.01% 3232
2023
Q4 		$787K Sell
13,622
-5,394
-28% -$276K ﹤0.01% 4696
2023
Q3 		$893K Buy
19,016
+7,322
+63% +$366K ﹤0.01% 4180
2023
Q2 		$519K Buy
11,694
+6,451
+123% +$229K ﹤0.01% 4798
2023
Q1 		$111K Sell
5,243
-1,872
-26% -$41.7K ﹤0.01% 5834
2022
Q4 		$142K Buy
7,115
+5,052
+245% +$252K ﹤0.01% 5773
2022
Q3 		$102K Sell
2,063
-2,553
-55% -$120K ﹤0.01% 5685
2022
Q2 		$234K Buy
+4,616
New +$204K ﹤0.01% 4790
2021
Q4 		– Sell
-43
Closed -$5K – 10470
2021
Q3 		$5K Buy
43
+29
+207% +$3.96K ﹤0.01% 8537
2021
Q2 		$3K Sell
14
-20
-59% -$6.58K ﹤0.01% 8811
2021
Q1 		$14K Buy
+34
New +$15.2K ﹤0.01% 7675

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's IRON Position: Q2 2026 in Review

UBS Group increased its Disc Medicine (IRON) stake by 13% in Q2 2026, buying an estimated $849K and bringing the position to 110,971 shares worth $8.12M. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

UBS Group first reported a position in IRON in Q1 2021 and has held it in 20 quarters since. The position peaked at $11.3M in Q3 2025. 215 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • UBS Group held 110,971 shares of Disc Medicine worth $8.12M as of Q2 2026.
  • UBS Group bought 12,350 Disc Medicine shares in Q2 2026, an estimated $849K.
  • Disc Medicine made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3681 holding.
  • UBS Group first reported a position in Disc Medicine in Q1 2021 and has held it in 20 quarters since.
  • UBS Group's Disc Medicine position peaked at $11.3M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.